EW

Edwards Lifesciences Corp. 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This summary covers the fiscal year ended December 31, 2025. Edwards Lifesciences is the leading global structural heart innovation company, focusing on transcatheter and surgical therapies for aortic, mitral, tricuspid, and pulmonic heart valves. The company operates in four geographic segments: United States, Europe, Japan, and Rest of World. In 2025, the company completed the sale of its non-core product group and previously divested its Critical Care product group in September 2024; results for these are reported as discontinued operations.

Key Financial Metrics

Note: Net Income from Continuing Operations excludes income from discontinued operations ($13.4 million in 2025 vs. $2,773.7 million in 2024).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 11.5% driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) (+9.3%) and Transcatheter Mitral and Tricuspid Therapies (TMTT) (+56.4%). TMTT growth was fueled by the PASCAL and EVOQUE systems.
• Profitability Decline: Despite revenue growth, operating income and net income from continuing operations declined significantly. This was primarily due to a $325.4 million increase in "Intellectual property agreement and certain litigation expenses" (up from $40.4 million in 2024) and a $146.9 million loss on impairment of investments.
• Discontinued Operations: The 2024 net income was heavily influenced by the sale of the Critical Care business. 2025 results reflect a normalized continuing operations profile.
• Tax Rate: The effective tax rate increased to 17.0% in 2025 from 9.8% in 2024, driven by Pillar Two global minimum tax provisions and non-deductible litigation expenses.

Guidance, Outlook, and Risks

• Strategic Focus: Management continues to invest heavily in R&D (18% of sales) to expand into heart failure management and non-valvular structural heart disease. Key product launches include the SAPIEN M3 mitral valve replacement system and KONECT RESILIA aortic valved conduit.
• Capital Allocation: The company repurchased 11.7 million shares in 2025 for $884.7 million. As of year-end, $2.0 billion remained available under the share repurchase program.
• Key Risks:
  • Litigation: Significant exposure to intellectual property disputes, including a $325.4 million expense in 2025 related to settlements and legal costs. Ongoing disputes include patent infringement claims regarding SAPIEN and PASCAL products.
  • Tax Uncertainty: A substantial uncertain tax position of $767.4 million exists, primarily related to intercompany transfer pricing. The IRS has issued a Notice of Deficiency for 2015-2017 tax years seeking an additional $269.3 million, which the company plans to contest judicially.
  • Regulatory & M&A: The FTC blocked the proposed acquisition of JenaValve in early 2026, resulting in a $99.8 million impairment charge on the bridge loan.

Investor Verification Checklist

• Litigation Exposure: Verify the status of the $325.4 million litigation expense and the potential for future accruals related to the Aortic Innovations and Cardiovalve lawsuits.
• Tax Liability: Assess the risk associated with the $767.4 million uncertain tax position and the outcome of the judicial contest regarding the IRS Notice of Deficiency.
• Investment Impairments: Review the details of the $146.9 million loss on impairment, specifically the JenaValve bridge loan and the decision not to exercise options on other medical device investments.
• TMTT Growth Sustainability: Evaluate whether the 56.4% growth in TMTT sales is sustainable given the smaller base and competitive landscape.
• Discontinued Operations: Confirm that future financial comparisons exclude the one-time gains from the Critical Care sale to accurately assess core business performance.